Hydroxyethyl substituted amineplatinum(II) and (IV) complexes are an interesting class of platinum based antitumour compounds due to their uncoordinated hydroxy groups. These hydroxy groups could play an important role in the mode of action of such complexes with respect to their ability to act as donor or acceptor for hydrogen bonds. Moreover, their chemistry in solution is of interest because it was found that there is the possibility of an intramolecular attack to form ethanolatoamine chelated species which are responsible for very stable monoadducts with 5'-GMP. Furthermore, there is the possibility of derivatisation at the OH site to form a new series of platinum compounds which may be used for a carrier mediated transport to tumour tissues. In this context a series of (N,N'-bis(2-hydroxyethyl)ethane-l,2-diamine)-platinum(II) complexes has been synthesised. During purification of one of the platinum based compounds, it was possible to isolate (SP-4-3)-R,S.(N,N'-bis(2-hydroxyethyl)ethane-l,2-diamine)malonatoplatinum(ll) and to resolve the structure by single crystal structure analysis. Intra-and intermolecular hydrogen bonds have been found which may explain the spontaneous crystallisation of the cis-R,S isomer and the stabilisation of the boat conformation of the malonatoplatinum(II) six-membered ring.
INTRODUCTION
Since the discovery of cisplatin, (NH3)2PtCI2 t'2j, as anticancer drug and its subsequent worldwide clinical application for the treatment of different types of tumoursE31, the synthesis and investigation of platinum compounds have become of interest. DNA is assumed to be the major target of a platinum based chemotherapyt41. After DNA platination (clear preference for N7 of guanine) replication and transcription are inhibited and apoptosis is induced. The application of cisplatin in therapy is limited by a variety of side effects including dose dependent nephrotoxicityESI. During the last decades, different strategies have been used to develop new platinum based anticancer compounds. Central points are reduction of toxicity and side effects, to increase the activity spectrum and to circumvent acquired cisplatin resistance of cells [6'7'8'9] . Therefore, thousands of platinum compounds have been synthesised and tested with respect to their anticancer activity. Nearly 30 entered clinical trials, but only carboplatin achieved worldwide approval and use. Based on a more detailed understanding of the mode of action of cisplatin and analogues, a rational drug design has started resulting in new platinum compounds and complexes which even violate the structure activity relationship" orally administrable platinum(IV) compounds, di-and trinuclear complexes, sterically hindered Pt coordination compounds, trans complexes and complexes with three nitrogen ligands.
In this context, we have synthesised mono-and bis(hydroxyethyl)substituted dianaineplatintm(ll/IV) I''-'l complexes which can be used for further derivatisation at the OH-group with respect to a carrier mediated transport of the cytotoxic moiety. Furthermore, the complexes themselves are very interesting because of their hydroxy-groups as a potential acceptor and/or donor for hydrogen bonds which could play an important role in the binding of platinum complexes to DNA. In addition, such complexes recently have shown an interesting behaviour in solution which resulted in very stable monoadducts with 5'-GMP ..41.
During the synthesis of a series of (N,N'-bis(2-hydroxyethyl)ethane-l,2-diamine)platinum(ll)complexes it was possible to isolate (SP-4-3)-R,S-(N,N'-bis(2-hydroxyethyl)ethane-l,2-diamine)malonatoplatinuna (ll) and to resolve its structure by single crystal structure analysis.
MATERIALS AND METHODS

Chemicals
All chemicals obtained from commercial suppliers were used as received and were of analytical grade. Water was used bidistilled. The synthetic procedures were carried out in a light protected environment. Sheldrick, 1997a ) [15] and subsequent Fourier and difference Fourier syntheses. Final structure parameters of the compound were obtained by full-matrix least squares techniques on F (SHELXL-97, Sheldrick, 1997b) [161. X-ray structure analysis data are given in Table I . Crystallographic data for the structure reported in this paper flare been deposited with the Cambridge Crystallographic Data Center as supplementary publication no. CCDC 155444 [171. Table I . X-Ray structure data of 1.
Molecular formula
C9HzoN207Pt
Formula weight (gmol") 463.36 Spa.ce group P2(1)/c a (A) 9 .086 (2) b (.A) 9 .267 (2) Elemental analyses were performed by the microanalytical laboratory at the University of Vienna.
Preparation of Platinum Complexes
The synthesis of the title compound (N,N'-bis(2-hydroxyethyl)ethane-l,2-diamine)malonatoplatinum(II) (Scheme 1) starts from potassium tetrachloroplatinate(II)and N,N'-bis(2-hydroxyethyl)ethane-l,2-diamine. After activation of the resulting platinum(II) complex with silver sulfate, the aquasulfato species was then reacted with the in situ formed sodium salt of malonic acid. After addition of acetone and filtration the solution was left at 4C to crystallize. Dichloro(N,N'-bis(2-hydroxyethyl)ethane-l,2-diamine)platinum(II In the H-and 3C NMR spectra of the crude product of (N,N'-bis(2-hydroxyethyl)ethane-l,2-diamine)malonatoplatinum(II) (Figure 2 ) which was obtained through addit'ion of acetone to the reaction mixture, filtration and crystallisation at 4C, more than one isomer could be detected B.K. Keppler et al.
Synthesis of (N,N'-Bi(2-Hydroxyethyl)Ethane-1,2-Diamine) Malonatoplatinum(lI) and X-ray Crystal Structure of the Cis-R, S-Isomer In the region between 2. A small singulett in the middle of the before mentioned dubletts at 3.55 which has no coupling to other protons in.the H,IH shift correlation spectrum is also visible indicating the presence of one or both optical transisomers (less than 10%).
In Synthesis of (N,N'-Bi(2-Hydroxyethyl)Ethane-1,2-Diamine) Malonatoplatinum(II) and X-ray Crystal Structure of the Cis-R, S-Isomer 40, 40 and 25 (half chair conformation: 13, 34, 42, 34 and 13) and in cyclohexane in the boat conformation 54, 0, 54, 54, 0 and 54 (chair conformation: 56). The structure of is stabilised by one intramolecular and four intermolecular hydrogen bonds in the crystal (Figure 3 and 5 ). 
